Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Indirab is a purified Vero cell rabies vaccine (PVRV) containing the inactivated Pitman-Moore strain of the rabies virus. Developed and manufactured by Bharat Biotech, it is indicated for both pre-exposure prophylaxis and post-exposure treatment of rabies in humans. The vaccine is produced by cultivating the virus in Vero cell cultures, followed by purification and inactivation with beta-propiolactone. Upon administration, Indirab stimulates the host immune system to produce specific neutralizing antibodies that provide active immunity against the rabies virus, a member of the Lyssavirus genus. It is recognized for its high potency and safety profile, serving as a modern alternative to older nerve-tissue-derived vaccines. The vaccine is typically administered via intramuscular or intradermal routes according to World Health Organization (WHO) recommended schedules.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rabies vaccine (Bharat Biotech).